- News Home
5 December 2013 11:26 am ,
Vol. 342 ,
An animal rights group known as the Nonhuman Rights Project filed lawsuits in three New York courts this week in an...
Researchers have been hot on the trail of the elusive Denisovans, a type of ancient human known only by their DNA and...
Thousands of scientists in the Russian Academy of Sciences (RAS) are about to lose their jobs as a result of the...
Dyslexia, a learning disability that hinders reading, hasn't been associated with deficits in vision, hearing, or...
Exotic, elusive, and dangerous, snakes have fascinated humankind for millennia. They can be hard to find, yet their...
Researchers have sequenced and analyzed the first two snake genomes, which represent two evolutionary extremes. The...
Snake venoms are remarkably complex mixtures that can stun or kill prey within minutes. But more and more researchers...
At age 30, Dutch biologist Freek Vonk has built up a respectable career as a snake scientist. But in his home country,...
- 5 December 2013 11:26 am , Vol. 342 , #6163
- About Us
Cutting Cancer's Supply Lines
23 January 1997 8:00 pm
Traditional cancer treatments attack the malignant cells directly, with surgery, radiation, or chemotherapy. But two studies to be reported tomorrow advance a promising new strategy: cutting off the blood vessels that deliver the oxygen and nutrients that tumors need to live and grow.
Philip Thorpe and his co-workers at the University of Texas Southwestern Medical Center in Dallas will report in Science that they can shrink or even eliminate tumors in mice with agents that trigger blood-clot formation in tumor-feeding vessels. And in Cell, Judah Folkman and his colleagues at Harvard Medical School describe the discovery of a natural compound that, by blocking the growth of new blood vessels in a tumor, can shrink large tumors down to microscopic size in mice.
To see tumors shrink so dramatically is ''outstanding ... better than my best hopes,'' says Noel Bouck of Northwestern University, who is also working on similar drugs. ''If it just works for human tumors, it will be fabulous.'' That's a big ''if,'' of course, but the strategy has a key advantage over many anticancer drugs, which falter as the cancer cells mutate into resistant forms. The cells of a tumor's blood vessels--the target of the new therapies--are normal and thus less prone to mutate than are cancer cells.
Both the Thorpe and Folkman teams' results build on 20 years' work, much of it from the Folkman group itself, showing that tumors not only need new blood vessels to grow, but secrete factors that stimulate blood-vessel formation. Since then, researchers have identified compounds that block the vessel growth, several of which are in early clinical trials. Now, the Folkman team has purified the most potent of these factors so far, which is secreted for unknown reasons by the cancer cells themselves.
Called endostatin, it attacked a wide variety of tumors in mice. When the animals were taken off the drug, the cancers regrew, but the treatment never lost its effectiveness. Each time it was restarted, the tumors shrank back to microscopic size. That result is ''unprecedented,'' says tumor biologist Bob Kerbel of the Sunnybrook Health Science Center at the University of Toronto. ''That would just never happen with chemotherapy.''
Thorpe took a different approach: destroying existing tumor blood vessels by inducing the cells lining them to make class II antigen, a protein they normally don't make. The researchers then took antibodies to class II antigen and linked them to a shortened version of another protein that triggers blood clotting. The team reasoned that by linking this protein to the antibody, they could direct it to the walls of the tumor blood vessels, causing clots to form specifically in those vessels.
The experiment ''worked like a charm,'' says Thorpe: The tumors were largely dead within 48 hours. But only the clinical trials planned for the next few years can show whether these charms will work for humans.
For more details, Science Online subscribers can link to the News story in today's Science.